JP2021090458A5 - - Google Patents

Download PDF

Info

Publication number
JP2021090458A5
JP2021090458A5 JP2021037024A JP2021037024A JP2021090458A5 JP 2021090458 A5 JP2021090458 A5 JP 2021090458A5 JP 2021037024 A JP2021037024 A JP 2021037024A JP 2021037024 A JP2021037024 A JP 2021037024A JP 2021090458 A5 JP2021090458 A5 JP 2021090458A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
seq
intron
moiety
exon
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021037024A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021090458A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2021090458A publication Critical patent/JP2021090458A/ja
Publication of JP2021090458A5 publication Critical patent/JP2021090458A5/ja
Pending legal-status Critical Current

Links

JP2021037024A 2015-03-18 2021-03-09 ミオスタチンにおけるアンチセンスに誘導されるエクソンの排除 Pending JP2021090458A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562135048P 2015-03-18 2015-03-18
US62/135,048 2015-03-18
US201562162571P 2015-05-15 2015-05-15
US62/162,571 2015-05-15

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2017548452A Division JP6942054B2 (ja) 2015-03-18 2016-03-18 ミオスタチンにおけるアンチセンスに誘導されるエクソンの排除

Publications (2)

Publication Number Publication Date
JP2021090458A JP2021090458A (ja) 2021-06-17
JP2021090458A5 true JP2021090458A5 (enExample) 2021-11-11

Family

ID=56919648

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017548452A Active JP6942054B2 (ja) 2015-03-18 2016-03-18 ミオスタチンにおけるアンチセンスに誘導されるエクソンの排除
JP2021037024A Pending JP2021090458A (ja) 2015-03-18 2021-03-09 ミオスタチンにおけるアンチセンスに誘導されるエクソンの排除

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2017548452A Active JP6942054B2 (ja) 2015-03-18 2016-03-18 ミオスタチンにおけるアンチセンスに誘導されるエクソンの排除

Country Status (6)

Country Link
US (2) US11015200B2 (enExample)
EP (1) EP3271372A4 (enExample)
JP (2) JP6942054B2 (enExample)
BR (1) BR112017019971A2 (enExample)
MA (1) MA41795A (enExample)
WO (1) WO2016149659A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2852549T3 (es) 2005-02-09 2021-09-13 Sarepta Therapeutics Inc Composición antisentido para tratamiento de la atrofia muscular
US20130085139A1 (en) 2011-10-04 2013-04-04 Royal Holloway And Bedford New College Oligomers
MA41795A (fr) 2015-03-18 2018-01-23 Sarepta Therapeutics Inc Exclusion d'un exon induite par des composés antisens dans la myostatine
WO2017047741A1 (ja) * 2015-09-16 2017-03-23 日本新薬株式会社 筋萎縮症治療用アンチセンス核酸
IL267632B2 (en) * 2016-12-30 2025-03-01 Olipass Corp Peptide Nucleic Acid Derivatives and their Uses
WO2020072125A1 (en) * 2018-10-03 2020-04-09 Massachusetts Institute Of Technology Splicing-dependent transcriptional gene silencing or activation
WO2021044004A1 (en) * 2019-09-05 2021-03-11 Sanofi Oligonucleotides containing nucleotide analogs
WO2022181532A1 (ja) * 2021-02-26 2022-09-01 学校法人神戸学院 ミオスタチンのスプライシングバリアントを発現させる核酸医薬

Family Cites Families (160)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4534899A (en) 1981-07-20 1985-08-13 Lipid Specialties, Inc. Synthetic phospholipid compounds
US4426330A (en) 1981-07-20 1984-01-17 Lipid Specialties, Inc. Synthetic phospholipid compounds
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
US5217866A (en) 1985-03-15 1993-06-08 Anti-Gene Development Group Polynucleotide assay reagent and method
JP3022967B2 (ja) 1985-03-15 2000-03-21 アンチバイラルズ インコーポレイテッド 立体規則性ポリヌクレオチド結合ポリマー
US5166315A (en) 1989-12-20 1992-11-24 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US5521063A (en) 1985-03-15 1996-05-28 Antivirals Inc. Polynucleotide reagent containing chiral subunits and methods of use
US5354844A (en) 1989-03-16 1994-10-11 Boehringer Ingelheim International Gmbh Protein-polycation conjugates
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5227170A (en) 1989-06-22 1993-07-13 Vestar, Inc. Encapsulation process
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5527528A (en) 1989-10-20 1996-06-18 Sequus Pharmaceuticals, Inc. Solid-tumor treatment method
US5356633A (en) 1989-10-20 1994-10-18 Liposome Technology, Inc. Method of treatment of inflamed tissues
US5469854A (en) 1989-12-22 1995-11-28 Imarx Pharmaceutical Corp. Methods of preparing gas-filled liposomes
US5580575A (en) 1989-12-22 1996-12-03 Imarx Pharmaceutical Corp. Therapeutic drug delivery systems
US5852188A (en) 1990-01-11 1998-12-22 Isis Pharmaceuticals, Inc. Oligonucleotides having chiral phosphorus linkages
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
JP3220180B2 (ja) 1991-05-23 2001-10-22 三菱化学株式会社 薬剤含有タンパク質結合リポソーム
US5719262A (en) 1993-11-22 1998-02-17 Buchardt, Deceased; Ole Peptide nucleic acids having amino acid side chains
US5714331A (en) 1991-05-24 1998-02-03 Buchardt, Deceased; Ole Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
US5539082A (en) 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
JPH07501204A (ja) 1991-06-28 1995-02-09 マサチューセッツ インスティテュート オブ テクノロジー 局所的オリゴヌクレオチド療法
NZ244306A (en) 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
US5521291A (en) 1991-09-30 1996-05-28 Boehringer Ingelheim International, Gmbh Conjugates for introducing nucleic acid into higher eucaryotic cells
FR2692265B1 (fr) 1992-05-25 1996-11-08 Centre Nat Rech Scient Composes biologiquement actifs de type phosphotriesters.
DE69330523T4 (de) 1992-08-21 2012-08-23 Vrije Universiteit Brussel Immunoglobuline ohne leichte ketten
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
US5583020A (en) 1992-11-24 1996-12-10 Ribozyme Pharmaceuticals, Inc. Permeability enhancers for negatively charged polynucleotides
JP3351476B2 (ja) 1993-01-22 2002-11-25 三菱化学株式会社 リン脂質誘導体及びそれを含有するリポソーム
US5395619A (en) 1993-03-03 1995-03-07 Liposome Technology, Inc. Lipid-polymer conjugates and liposomes
US5994618A (en) 1997-02-05 1999-11-30 Johns Hopkins University School Of Medicine Growth differentiation factor-8 transgenic mice
WO1994021681A1 (en) 1993-03-19 1994-09-29 Johns Hopkins University School Of Medicine Growth differentiation factor-8
US20030074680A1 (en) 1993-03-19 2003-04-17 Johns Hopkins University School Of Medicine Growth differentiation factor-8
US5462854A (en) 1993-04-19 1995-10-31 Beckman Instruments, Inc. Inverse linkage oligonucleotides for chemical and enzymatic processes
US6838254B1 (en) 1993-04-29 2005-01-04 Conopco, Inc. Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of camelidae
DE69435005T2 (de) 1993-05-11 2008-04-17 The University Of North Carolina At Chapel Hill Antisense Oligonukleotide die anomales Splicing verhindern und deren Verwendung
FR2705099B1 (fr) 1993-05-12 1995-08-04 Centre Nat Rech Scient Oligonucléotides phosphorothioates triesters et procédé de préparation.
US5534259A (en) 1993-07-08 1996-07-09 Liposome Technology, Inc. Polymer compound and coated particle composition
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
US5417978A (en) 1993-07-29 1995-05-23 Board Of Regents, The University Of Texas System Liposomal antisense methyl phosphonate oligonucleotides and methods for their preparation and use
US6060456A (en) 1993-11-16 2000-05-09 Genta Incorporated Chimeric oligonucleoside compounds
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US5543152A (en) 1994-06-20 1996-08-06 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5591721A (en) 1994-10-25 1997-01-07 Hybridon, Inc. Method of down-regulating gene expression
US5512295A (en) 1994-11-10 1996-04-30 The Board Of Trustees Of The Leland Stanford Junior University Synthetic liposomes for enhanced uptake and delivery
US5707618A (en) 1995-03-24 1998-01-13 Genzyme Corporation Adenovirus vectors for gene therapy
TW311927B (enExample) 1995-07-11 1997-08-01 Minnesota Mining & Mfg
US5874500A (en) 1995-12-18 1999-02-23 Cohesion Technologies, Inc. Crosslinked polymer compositions and methods for their use
US7803782B2 (en) 2003-05-28 2010-09-28 Roche Madison Inc. Intravenous delivery of polynucleotides to cells in mammalian limb
US6245747B1 (en) 1996-03-12 2001-06-12 The Board Of Regents Of The University Of Nebraska Targeted site specific antisense oligodeoxynucleotide delivery method
AU729643B2 (en) 1996-05-01 2001-02-08 Antivirals Inc. Polypeptide conjugates for transporting substances across cell membranes
IL132941A0 (en) 1997-05-21 2001-03-19 Univ Leland Stanford Junior Composition and method for enhancing transport across biological membranes
ES2547858T3 (es) 1997-07-14 2015-10-09 Université de Liège Doble musculación en mamíferos
US6103466A (en) 1997-07-14 2000-08-15 University Of Liege Double-muscling in mammals
US6133246A (en) 1997-08-13 2000-10-17 Isis Pharmaceuticals Inc. Antisense oligonucleotide compositions and methods for the modulation of JNK proteins
US7572582B2 (en) 1997-09-12 2009-08-11 Exiqon A/S Oligonucleotide analogues
US6794499B2 (en) 1997-09-12 2004-09-21 Exiqon A/S Oligonucleotide analogues
US6228579B1 (en) 1997-11-14 2001-05-08 San Diego State University Foundation Method for identifying microbial proliferation genes
US6210892B1 (en) 1998-10-07 2001-04-03 Isis Pharmaceuticals, Inc. Alteration of cellular behavior by antisense modulation of mRNA processing
US6172216B1 (en) 1998-10-07 2001-01-09 Isis Pharmaceuticals Inc. Antisense modulation of BCL-X expression
US6214986B1 (en) 1998-10-07 2001-04-10 Isis Pharmaceuticals, Inc. Antisense modulation of bcl-x expression
EP1173561A2 (en) 1999-01-29 2002-01-23 Avi Biopharma, Inc. Non-invasive method for detecting target rna
US7094765B1 (en) 1999-01-29 2006-08-22 Avi Biopharma, Inc. Antisense restenosis composition and method
US7084125B2 (en) 1999-03-18 2006-08-01 Exiqon A/S Xylo-LNA analogues
CA2372085C (en) 1999-05-04 2009-10-27 Exiqon A/S L-ribo-lna analogues
US6284882B1 (en) 1999-06-10 2001-09-04 Abbott Laboratories Myostatin gene promoter and inhibition of activation thereof
EP1072680A1 (en) 1999-07-30 2001-01-31 Pfizer Products Inc. Myostatin regulatory region, nucleotide sequence determination and methods for its use
US6669951B2 (en) 1999-08-24 2003-12-30 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into epithelial tissues
DE60038695T2 (de) 1999-11-29 2009-05-28 Avi Biopharma, Inc., Corvallis Gegen bakterielle 16s und 23s rrnas gerichtete ungeladene antisense oligonukleotide und deren verwendungen
WO2001049775A2 (en) 2000-01-04 2001-07-12 Avi Biopharma, Inc. Antisense antibacterial cell division composition and method
US6287860B1 (en) 2000-01-20 2001-09-11 Isis Pharmaceuticals, Inc. Antisense inhibition of MEKK2 expression
CA2400573A1 (en) 2000-03-28 2001-10-04 Isis Pharmaceuticals Inc. Alteration of cellular behavior by antisense modulation of mrna processing
US6653467B1 (en) 2000-04-26 2003-11-25 Jcr Pharmaceutical Co., Ltd. Medicament for treatment of Duchenne muscular dystrophy
KR20020097241A (ko) 2000-05-04 2002-12-31 에이브이아이 바이오파마 인코포레이티드 스플라이스-영역 안티센스 조성물 및 방법
EP3020804A1 (en) 2000-07-06 2016-05-18 Sarepta Therapeutics, Inc. Transforming growth factor beta (tgf- ) blocking agent-treated stem cell composition and method
EP1191097A1 (en) 2000-09-21 2002-03-27 Leids Universitair Medisch Centrum Induction of exon skipping in eukaryotic cells
US20050124566A1 (en) 2001-05-18 2005-06-09 Sirna Therapeutics, Inc. RNA interference mediated inhibition of myostatin gene expression using short interfering nucleic acid (siNA)
JP2005514005A (ja) 2001-09-04 2005-05-19 エクシコン エ／エス 新規のｌｎａ組成物およびその使用
AU2002342057B2 (en) 2001-10-16 2009-01-22 Avi Biopharma, Inc. Antisense antiviral agent and method for treating ssRNA viral infection
US6965025B2 (en) 2001-12-10 2005-11-15 Isis Pharmaceuticals, Inc. Antisense modulation of connective tissue growth factor expression
JP2003203451A (ja) 2001-12-28 2003-07-18 Fujitsu Ltd ヘッドスライダ
KR100464261B1 (ko) 2002-01-24 2005-01-03 주식회사 파나진 Ｐｎａ 올리고머를 합성하기 위한 신규한 단량체 및 그의제조방법
US20090099117A1 (en) 2002-02-20 2009-04-16 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF MYOSTATIN GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
KR20030084444A (ko) 2002-04-26 2003-11-01 주식회사 파나진 Ｐｎａ 올리고머를 합성하기 위한 신규한 단량체 및 그의제조방법
US7569575B2 (en) 2002-05-08 2009-08-04 Santaris Pharma A/S Synthesis of locked nucleic acid derivatives
AU2003287464A1 (en) 2002-11-05 2004-06-03 Isis Pharmaceuticals, Inc. 2'-fluoro substituted oligomeric compounds and compositions for use in gene modulations
US7250496B2 (en) 2002-11-14 2007-07-31 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory genes and uses thereof
WO2004083432A1 (en) 2003-03-21 2004-09-30 Academisch Ziekenhuis Leiden Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure
CA2523672C (en) 2003-04-29 2012-07-17 Avi Biopharma, Inc. Compositions for enhancing transport of molecules into cells
US7211668B2 (en) 2003-07-28 2007-05-01 Panagene, Inc. PNA monomer and precursor
US20050234002A1 (en) 2004-01-23 2005-10-20 Mourich Dan V Antisense oligomers and methods for inducing immune tolerance and immunosuppression
EP3006039B1 (en) 2004-03-02 2021-01-06 Acceleron Pharma Inc. Alk7 polypeptides for use in promoting fat loss
WO2005107447A2 (en) 2004-05-11 2005-11-17 Ingenium Pharmaceuticals Ag Methods for the production of improved live stocks and disease models for therapeutic research
EP3808845A1 (en) 2004-06-28 2021-04-21 The University Of Western Australia Antisense oligonucleotides for inducing exon skipping and methods of use thereof
NZ538097A (en) 2005-02-07 2006-07-28 Ovita Ltd Method and compositions for improving wound healing
AU2015203791B2 (en) 2005-02-09 2017-06-29 Sarepta Therapeutics, Inc. Antisense composition and method for treating
ES2852549T3 (es) * 2005-02-09 2021-09-13 Sarepta Therapeutics Inc Composición antisentido para tratamiento de la atrofia muscular
CA2605512A1 (en) 2005-04-22 2006-10-26 Academisch Ziekenhuis Leiden Modulation of exon recognition in pre-mrna by interfering with the binding of sr proteins and by interfering with secondary rna structure.
EP1877075A4 (en) 2005-04-25 2008-07-30 Pfizer ANTIBODY TO MYOSTATIN
CA2538208A1 (en) 2005-05-04 2006-11-04 Universite Laval Modulation of myostatin and use thereof in cell transplantation-based treatment of muscle disease
PL1910395T3 (pl) 2005-06-23 2013-03-29 Cold Spring Harbor Laboratory Kompozycja i sposób modulacji splicingu SMN2
WO2007003216A1 (en) 2005-07-06 2007-01-11 Universidad Autónoma de Madrid Anti-ccr7 receptor antibodies for the treatment of cancer
US8501704B2 (en) 2005-11-08 2013-08-06 Sarepta Therapeutics, Inc. Immunosuppression compound and treatment method
US7785834B2 (en) 2005-11-10 2010-08-31 Ercole Biotech, Inc. Soluble TNF receptors and their use in treatment of disease
CA2629323A1 (en) 2005-11-10 2007-05-24 The University Of North Carolina At Chapel Hill Splice switching oligomers for tnf superfamily receptors and their use in treatment of disease
PL2735568T3 (pl) * 2006-05-10 2018-02-28 Sarepta Therapeutics, Inc. Analogi oligonukleotydowe mające kationowe połączenia pomiędzy podjednostkami
EP1857548A1 (en) 2006-05-19 2007-11-21 Academisch Ziekenhuis Leiden Means and method for inducing exon-skipping
US8097596B2 (en) 2006-06-30 2012-01-17 Lakewood-Amedex, Inc. Compositions and methods for the treatment of muscle wasting
WO2008005019A1 (en) 2006-07-07 2008-01-10 Dale Roderic M K Compositions and methods for the treatment of muscle wasting
CA2666981A1 (en) 2006-10-20 2008-05-02 Ercole Biotech, Inc. Soluble tnf receptors and their use in treatment of disease
US20090264353A1 (en) 2007-10-19 2009-10-22 Santaris Pharma A/S Splice Switching Oligomers for TNF Superfamily Receptors and their Use in Treatment of Disease
TW202104248A (zh) 2007-02-02 2021-02-01 美商艾瑟勒朗法瑪公司 衍生自ActRIIB的變體與其用途
CA3072221A1 (en) 2007-05-01 2008-11-06 Santaris Pharma A/S Splice switching oligomers for tnf superfamily receptors and their use in treatment of disease
WO2008153933A2 (en) 2007-06-06 2008-12-18 Avi Biopharma, Inc. Soluble her2 and her3 splice variant proteins, splice-switching oligonucleotides, and their use in the treatment of disease
EP2170363B1 (en) 2007-06-29 2018-08-08 Sarepta Therapeutics, Inc. Tissue specific peptide conjugates and methods
US20100016215A1 (en) 2007-06-29 2010-01-21 Avi Biopharma, Inc. Compound and method for treating myotonic dystrophy
CA2693742A1 (en) 2007-07-12 2009-01-15 Prosensa Technologies B.V. Molecules for targeting compounds to various selected organs, tissues or tumor cells
US7935816B2 (en) 2007-10-25 2011-05-03 Gene Tools, Llc Molecular transporter compositions comprising dendrimeric oligoguanidine with a triazine core that facilitate delivery into cells in vivo
PT2203173E (pt) 2007-10-26 2016-03-15 Academisch Ziekenhuis Leiden Resumo
US8076476B2 (en) 2007-11-15 2011-12-13 Avi Biopharma, Inc. Synthesis of morpholino oligomers using doubly protected guanine morpholino subunits
WO2009064471A1 (en) 2007-11-15 2009-05-22 Avi Biopharma, Inc. Method of synthesis of morpholino oligomers
CA2710013A1 (en) 2007-12-28 2009-07-09 Avi Biopharma, Inc. Immunomodulatory agents and methods of use
WO2009088895A2 (en) 2008-01-04 2009-07-16 Cue Acoustics, Inc. Audio device with integrated switching power supply
EP2119783A1 (en) 2008-05-14 2009-11-18 Prosensa Technologies B.V. Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means
US8236557B2 (en) 2008-05-28 2012-08-07 University Of Missouri-Columbia Hybrid-AAV vectors to deliver large gene expression cassette
TWI748373B (zh) 2008-08-14 2021-12-01 美商艾瑟勒朗法瑪公司 使用gdf阱以增加紅血球水平
US8084601B2 (en) 2008-09-11 2011-12-27 Royal Holloway And Bedford New College Royal Holloway, University Of London Oligomers
CA3066050A1 (en) 2008-10-24 2010-04-29 Sarepta Therapeutics, Inc. Multiple exon skipping compositions for dmd
GB0821457D0 (en) * 2008-11-24 2008-12-31 Trillion Genomics Ltd Oligonucleotides
AU2009335740B2 (en) 2008-12-17 2016-04-21 Sarepta Therapeutics, Inc. Antisense compositions and methods for modulating contact hypersensitivity or contact dermatitis
EP2417257B1 (en) 2009-04-10 2016-03-09 Association Institut de Myologie Tricyclo-dna antisense oligonucleotides, compositions, and methods for the treatment of disease
US20120149757A1 (en) 2009-04-13 2012-06-14 Krainer Adrian R Compositions and methods for modulation of smn2 splicing
ES2593836T3 (es) 2009-04-24 2016-12-13 Biomarin Technologies B.V. Oligonucleótido que comprende una inosina para tratar la DMD
EP2424895B1 (en) 2009-04-27 2017-09-06 Novartis AG Compositions and methods for increasing muscle growth
WO2010129406A2 (en) 2009-05-04 2010-11-11 The Johns Hopkins University Methods of promoting muscle growth
NZ597071A (en) 2009-06-17 2014-05-30 Isis Pharmaceuticals Inc Compositions and methods for modulation of smn2 splicing in a subject
SI2499249T1 (sl) 2009-11-12 2019-02-28 The University Of Western Australia, Protismiselne molekule in postopki zdravljenja patologij
US8802642B2 (en) 2010-04-28 2014-08-12 Iowa State University Research Foundation, Inc. Spinal muscular atrophy treatment via targeting SMN2 catalytic core
KR102095478B1 (ko) * 2010-05-28 2020-04-01 사렙타 쎄러퓨틱스, 인코퍼레이티드 변형된 서브유니트간 결합 및/또는 말단 그룹을 갖는 올리고뉴클레오타이드 유사체
TWI541024B (zh) 2010-09-01 2016-07-11 日本新藥股份有限公司 反義核酸
HUE030292T2 (en) 2010-09-30 2017-04-28 Nippon Shinyaku Co Ltd Morpholino-nucleic acid derivatives
CA2826836A1 (en) 2011-02-08 2012-08-16 The Charlotte-Mecklenburg Hospital Authority D/B/A Carolinas Medical Center Antisense oligonucleotides
KR102339196B1 (ko) 2011-05-05 2021-12-15 사렙타 쎄러퓨틱스, 인코퍼레이티드 펩타이드 올리고뉴클레오타이드 접합체
US20130085139A1 (en) 2011-10-04 2013-04-04 Royal Holloway And Bedford New College Oligomers
ES2535654T3 (es) 2011-10-13 2015-05-13 Association Institut De Myologie ADN triciclo-fosforotioato
HK1201514A1 (en) 2011-11-18 2015-09-04 Sarepta Therapeutics, Inc. Functionally-modified oligonucleotides and subunits thereof
WO2013078316A1 (en) 2011-11-23 2013-05-30 Nationwide Children's Hospital, Inc. Recombinant adeno-associated virus delivery of alpha-sarcoglycan polynucleotides
CN117721110A (zh) 2011-12-28 2024-03-19 日本新药株式会社 反义核酸
CA2862628C (en) 2012-01-27 2021-08-24 Prosensa Technologies B.V. Rna modulating oligonucleotides with improved characteristics for the treatment of duchenne and becker muscular dystrophy
JP6460983B2 (ja) 2012-07-03 2019-01-30 バイオマリン テクノロジーズ ベー．フェー． 筋ジストロフィー患者の治療のためのオリゴヌクレオチド
EP3885439A1 (en) 2012-12-20 2021-09-29 Sarepta Therapeutics, Inc. Improved exon skipping compositions for treating muscular dystrophy
IL280443B (en) 2013-03-14 2022-07-01 Sarepta Therapeutics Inc Preparations that skip axon for the treatment of muscular dystrophy
MX373959B (es) 2013-03-15 2020-07-13 Sarepta Therapeutics Inc Composición para usarse en el tratamiento de la distrofia muscular de duchenne (dmd).
WO2014172448A2 (en) 2013-04-17 2014-10-23 Anaptysbio, Inc. Antibodies directed against activin receptor type ii (actrii)
TWI736514B (zh) * 2013-09-05 2021-08-21 美商薩羅塔治療公司 酸性α葡萄糖苷酶之反義股誘導之外顯子２包含
MA41795A (fr) 2015-03-18 2018-01-23 Sarepta Therapeutics Inc Exclusion d'un exon induite par des composés antisens dans la myostatine
MA45819A (fr) 2015-10-09 2018-08-15 Sarepta Therapeutics Inc Compositions et méthodes pour traiter la dystrophie musculaire de duchenne et troubles associés
JP2021026584A (ja) 2019-08-07 2021-02-22 ｉ Ｓｍａｒｔ Ｔｅｃｈｎｏｌｏｇｉｅｓ株式会社 改善対策リコメンドシステム

Similar Documents

Publication Publication Date Title
JP2021090458A5 (enExample)
Mahmoud et al. Antiviral nucleoside and nucleotide analogs: a review
ES2244957T3 (es) Oligonucleotidos modificados, su preparacion, asi como su empleo.
EP0707481B1 (en) L-2',3'-dideoxy nucleoside analogs as anti-hepatitis b (hbv) and anti-hiv agents
US6833361B2 (en) Nucleosides having bicyclic sugar moiety
JP2007504830A5 (enExample)
US20060074035A1 (en) Dinucleotide inhibitors of de novo RNA polymerases for treatment or prevention of viral infections
JP2018530560A5 (enExample)
CA2103721A1 (en) Methylene phosphonate nucleoside analogs and oligonucleotide analogs made therefrom
JP2016502858A5 (enExample)
CA2904692A1 (en) Modified 4'-nucleosides as antiviral agents
US20020160969A1 (en) Nucleosides and oligonucleotides containing boron clusters
JP2017513469A5 (enExample)
JPH05504553A (ja) 新規の結合を有するオリゴヌクレオチドアナログ
JPWO2019157531A5 (enExample)
ES2329428T3 (es) Derivados de 5'-deoxi-citidina.
AR127325A1 (es) Métodos y composiciones para el tratamiento de la enfermedad renal poliquística
JP2021182946A5 (enExample)
JP2018538302A5 (enExample)
JP2018525015A5 (enExample)
ES2496946T3 (es) Derivados de nucleótidos de purina
JP2018518167A5 (enExample)
JPH03504970A (ja) ２′，５′―オリゴアデニレート誘導体の治療的使用
AU664883B2 (en) Dual action 2',5'-oligoadenylate antiviral derivatives and uses thereof
EP0799834A1 (en) Modified nucleotides